Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 4,600,000 shares, a decrease of 12.0% from the September 15th total of 5,230,000 shares. Based on an average trading volume of 389,800 shares, the short-interest ratio is currently 11.8 days. Approximately 18.6% of the shares of the company are short sold.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in shares of Arcturus Therapeutics in the 1st quarter worth approximately $40,000. Quest Partners LLC boosted its position in Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after buying an additional 3,579 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Arcturus Therapeutics during the second quarter valued at about $142,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after buying an additional 428 shares during the period. Finally, Public Employees Retirement System of Ohio lifted its stake in shares of Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock valued at $156,000 after acquiring an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ARCT shares. Leerink Partners initiated coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They set an "outperform" rating and a $70.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Finally, Leerink Partnrs raised shares of Arcturus Therapeutics to a "strong-buy" rating in a report on Monday, August 12th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $71.40.

Arcturus Therapeutics Stock Down 2.5 %

Shares of ARCT stock traded down $0.54 during trading on Monday, hitting $20.92. The company had a trading volume of 295,266 shares, compared to its average volume of 481,222. The stock's 50-day moving average is $20.97 and its two-hundred day moving average is $25.75. The stock has a market capitalization of $563.42 million, a price-to-earnings ratio of -5.27 and a beta of 2.61. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. During the same quarter in the prior year, the firm earned ($1.98) EPS. On average, research analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.